NRx Pharmaceuticals, Inc. announced that the Class I directors are Chaim Hurvitz and Daniel Troy, and their terms will expire at 2022 annual meeting of stockholders. Daniel Troy will not be standing for reelection to the Board.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.865 USD | +36.43% | -24.23% | -41.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.52% | 21.88M | |
+21.76% | 47.9B | |
+46.62% | 41.42B | |
-2.18% | 40.7B | |
-6.20% | 28.92B | |
+10.19% | 25.55B | |
-20.87% | 19.27B | |
-0.32% | 12.15B | |
+31.04% | 12.14B | |
-0.47% | 11.99B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- Nrx Pharmaceuticals, Inc. Announces Director Resignation